LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Pictilisib | 1.11 | uM | LJP6 | 72 | hr | 1311 | 3702 | 4935 | 0.7501 | 0.7205 |
MDA-MB-231 | Pictilisib | 3.33 | uM | LJP6 | 72 | hr | 1311 | 3377 | 4935 | 0.6842 | 0.6395 |
MDA-MB-231 | Pictilisib | 10 | uM | LJP6 | 72 | hr | 1311 | 2597 | 4935 | 0.5263 | 0.4295 |
MDA-MB-231 | PD184352 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 5023 | 5079 | 0.9891 | 0.9889 |
MDA-MB-231 | PD184352 | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4341 | 5079 | 0.8547 | 0.8453 |
MDA-MB-231 | PD184352 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 4016 | 5079 | 0.7908 | 0.7734 |
MDA-MB-231 | PD184352 | 1.11 | uM | LJP5 | 72 | hr | 1311 | 3403 | 5079 | 0.6701 | 0.6292 |
MDA-MB-231 | PD184352 | 3.33 | uM | LJP5 | 72 | hr | 1311 | 2896 | 5079 | 0.5704 | 0.5003 |
MDA-MB-231 | PD184352 | 10 | uM | LJP5 | 72 | hr | 1311 | 1877 | 5079 | 0.3697 | 0.2016 |
MDA-MB-231 | PLX-4720 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 5160 | 5079 | 1.0161 | 1.0162 |
MDA-MB-231 | PLX-4720 | 0.12 | uM | LJP5 | 72 | hr | 1311 | 5140 | 5079 | 1.0119 | 1.0120 |
MDA-MB-231 | PLX-4720 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 5164 | 5079 | 1.0168 | 1.0168 |
MDA-MB-231 | PLX-4720 | 1.11 | uM | LJP5 | 72 | hr | 1311 | 4897 | 5079 | 0.9641 | 0.9628 |
MDA-MB-231 | PLX-4720 | 3.33 | uM | LJP5 | 72 | hr | 1311 | 4469 | 5079 | 0.8795 | 0.8717 |
MDA-MB-231 | PLX-4720 | 10 | uM | LJP5 | 72 | hr | 1311 | 3679 | 5079 | 0.7239 | 0.6926 |
MDA-MB-231 | Lapatinib | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4495 | 4935 | 0.9111 | 0.9049 |
MDA-MB-231 | Lapatinib | 0.12 | uM | LJP6 | 72 | hr | 1311 | 4692 | 4935 | 0.9506 | 0.9472 |
MDA-MB-231 | Lapatinib | 0.37 | uM | LJP6 | 72 | hr | 1311 | 4748 | 4935 | 0.9619 | 0.9596 |
MDA-MB-231 | Lapatinib | 1.11 | uM | LJP6 | 72 | hr | 1311 | 4650 | 4935 | 0.9421 | 0.9385 |
MDA-MB-231 | Lapatinib | 3.33 | uM | LJP6 | 72 | hr | 1311 | 4638 | 4935 | 0.9397 | 0.9358 |
MDA-MB-231 | Lapatinib | 10 | uM | LJP6 | 72 | hr | 1311 | 3377 | 4935 | 0.6844 | 0.6398 |
MDA-MB-231 | Sirolimus | 0.04 | uM | LJP6 | 72 | hr | 1311 | 4261 | 4935 | 0.8639 | 0.8518 |
MDA-MB-231 | Sirolimus | 0.12 | uM | LJP6 | 72 | hr | 1311 | 4149 | 4935 | 0.8410 | 0.8265 |
MDA-MB-231 | Sirolimus | 0.37 | uM | LJP6 | 72 | hr | 1311 | 4250 | 4935 | 0.8614 | 0.8492 |
MDA-MB-231 | Sirolimus | 1.11 | uM | LJP6 | 72 | hr | 1311 | 4180 | 4935 | 0.8472 | 0.8335 |